header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-PUB-110609-35
Abnormal mitoferrin-1 expression in patients with erythropoietic protoporphyria
Wang, Y., Langer, N.B., Shaw, G.C., Yang, G., Li, L., Kaplan, J., Paw, B.H., and Bloomer, J.R.
Date: 2011
Source: Experimental hematology 39(7): 784-94 (Journal)
Registered Authors: Paw, Barry, Shaw, George C.
Keywords: none
MeSH Terms:
  • 5-Aminolevulinate Synthetase/genetics
  • 5-Aminolevulinate Synthetase/metabolism
  • Adolescent
  • Adult
  • Aged
  • Animals
  • Base Sequence
  • COS Cells
  • Cation Transport Proteins/genetics*
  • Cation Transport Proteins/metabolism
  • Cercopithecus aethiops
  • Child
  • Embryo, Nonmammalian/embryology
  • Embryo, Nonmammalian/metabolism
  • Female
  • Ferrochelatase/genetics*
  • Ferrochelatase/metabolism
  • Gene Expression*
  • Genetic Complementation Test
  • Humans
  • K562 Cells
  • Male
  • Middle Aged
  • Mitochondrial Proteins/genetics*
  • Mitochondrial Proteins/metabolism
  • Molecular Sequence Data
  • Mutation
  • Protoporphyria, Erythropoietic/genetics*
  • Protoporphyria, Erythropoietic/metabolism
  • Protoporphyria, Erythropoietic/pathology
  • RNA, Messenger/genetics
  • RNA, Messenger/metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Xenopus/embryology
  • Xenopus/genetics
  • Yeasts/genetics
  • Yeasts/growth & development
  • Young Adult
PubMed: 21627978 Full text @ Exp. Hematol.
FIGURES
ABSTRACT

OBJECTIVE:

Most patients with erythropoietic protoporphyria have deficient ferrochelatase (FECH) activity due to changes in FECH DNA. We evaluated seven patients with erythropoietic protoporphyria phenotype in whom abnormalities of FECH DNA were not found by conventional analysis. The major focus was mitoferrin-1 (MFRN1), the mitochondrial transporter of Fe used for heme formation by FECH and for 2Fe2S cluster synthesis, which is critical to FECH activity/stability.

MATERIALS AND METHODS:

Four patients had a deletion in ALAS2 that causes enzyme gain-of-function, resulting in increased formation of protoporphyrin; one had a heterozygous major deletion in FECH DNA. All had an abnormal transcript of MFRN1 in messenger RNA extracted from blood leukocytes and/or liver tissue. The abnormal transcript contained an insert of intron 2 that had a stop codon. The consequences of abnormal MFRN1 expression were examined using zebrafish and yeast MFRN-deficient strains and cultured lymphoblasts from the patients.

RESULTS:

Abnormal human MFRN1 complementary DNA showed loss-of-function in zebrafish and yeast mutants, whereas normal human MFRN1 complementary DNA rescued both. Using cultured lymphoblasts, quantitative reverse transcription polymerase chain reaction showed increased formation of abnormal transcript that was accompanied by decreased formation of normal transcript and reduced FECH activity in patients compared to normal lines. A positive correlation coefficient (0.75) was found between FECH activity and normal MFRN1 messenger RNA in lymphoblasts. However, no obvious cause for increased formation of abnormal transcript was identified in MFRN1 exons and splice junctions.

CONCLUSIONS:

Abnormal MFRN1 expression can contribute to erythropoietic protoporphyria phenotype in some patients, probably by causing a reduction in FECH activity.

ADDITIONAL INFORMATION